Literature DB >> 12594955

Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing.

Kevin R Bobbitt1, Marylyn M Addo, Marcus Altfeld, Tracey Filzen, Adewunmi A Onafuwa, Bruce D Walker, Kathleen L Collins.   

Abstract

The HIV Nef protein is thought to promote HIV immune evasion by downmodulating MHC-I and protecting infected cells from CTL killing. In addition, we demonstrated that Rev, an HIV regulatory protein needed for expression of the HIV late genes, can influence CTL killing. When Rev activity level was reduced by virtue of amino acid alterations in the Rev protein sequence, infected cells were more resistant to anti-Gag and anti-Env CTL killing. A screen of primary viral isolates revealed that viruses derived from asymptomatic, infected people had lower Rev activity, lower Gag levels, and greater resistance to anti-Gag CTL killing. Thus, rev alleles with low activity may have a selective advantage in infected people with effective immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594955     DOI: 10.1016/s1074-7613(03)00031-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  19 in total

1.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Tracey M Filzen; Kathleen L Collins
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Rev-RRE Functional Activity Differs Substantially Among Primary HIV-1 Isolates.

Authors:  Patrick E Jackson; Denis M Tebit; David Rekosh; Marie-Louise Hammarskjold
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-03       Impact factor: 2.205

Review 5.  Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.

Authors:  Nadia T Sebastian; Kathleen L Collins
Journal:  Expert Rev Anti Infect Ther       Date:  2014-09-04       Impact factor: 5.091

6.  Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study.

Authors:  Jeremy Seto; Liang Qiao; Carolin A Guenzel; Sa Xiao; Megan L Shaw; Fernand Hayot; Stuart C Sealfon
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

7.  Naturally arising point mutations in non-essential domains of equine infectious anemia virus Rev alter Rev-dependent nuclear-export activity.

Authors:  Wendy O Sparks; Karin S Dorman; Sijun Liu; Susan Carpenter
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

8.  Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Authors:  Diana M Brainard; William G Tharp; Elva Granado; Nicholas Miller; Alicja K Trocha; Xiang-Hui Ren; Brian Conrad; Ernest F Terwilliger; Richard Wyatt; Bruce D Walker; Mark C Poznansky
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization.

Authors:  Emily A Sloan; Mary F Kearney; Laurie R Gray; Kathryn Anastos; Eric S Daar; Joseph Margolick; Frank Maldarelli; Marie-Louise Hammarskjold; David Rekosh
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

10.  Sequence and Functional Variation in the HIV-1 Rev Regulatory Axis.

Authors:  Patrick E H Jackson; Godfrey Dzhivhuho; David Rekosh; Marie-Louise Hammarskjold
Journal:  Curr HIV Res       Date:  2020       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.